Literature DB >> 25048864

Bladder cancer: Defining intermediate-risk non-muscle-invasive bladder cancer.

S Bruce Malkowicz1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25048864     DOI： 10.1038/nrurol.2014.172

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.

Authors:  Savino M Di Stasi; Marco Valenti; Cristian Verri; Emanuele Liberati; Arcangelo Giurioli; Gioia Leprini; Francesco Masedu; Antonio R Ricci; Francesco Micali; Giuseppe Vespasiani
Journal:  Lancet Oncol       Date:  2011-08-08       Impact factor: 41.316

Review 2.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

Review 3.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

Review 4.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Authors:  Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

5.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

Review 6.  Update on intravesical agents for non-muscle-invasive bladder cancer.

Authors:  Shahrokh F Shariat; Daher C Chade; Pierre I Karakiewicz; Douglas S Scherr; Guido Dalbagni
Journal:  Immunotherapy       Date:  2010-05       Impact factor: 4.196

7.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; Adrian P M van der Meijden
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

8.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.